ACE-031 vs Gonadorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
ACE-031
Soluble form of activin type IIB receptor (ActRIIB-Fc fusion protein) that acts as a myostatin and activin trap. Blocks the primary signals that limit muscle growth by sequestering myostatin, activin, and related ligands before they reach cell surface receptors. Phase 2 trials in Duchenne muscular dystrophy demonstrated significant lean mass increases.
Full profileGonadorelin
Synthetic form of endogenous gonadotropin-releasing hormone (GnRH) that stimulates LH and FSH release from the anterior pituitary. Used in TRT protocols to maintain testicular function and prevent atrophy during exogenous testosterone administration. Preserves spermatogenesis and endogenous testosterone production capacity.
Full profile| ACE-031 | Gonadorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | ACVR2B-Fc, ActRIIB-Fc fusion protein | GnRH, gonadotropin-releasing hormone, Factrel, Lutrepulse |
| Evidence | Investigational (in trials) | Research-stage |
| Dosing range | 0.3mg/kg–3mg/kg mg/kg, every 2–4 weeks (subcutaneous injection) | 50mcg–200mcg mcg, 2–3x per week subcutaneous |
| Administration | Subcutaneous injection | Subcutaneous injection, Intranasal (pulsatile delivery) |
| Key side effects | Nosebleeds (epistaxis — most common reported AE), Telangiectasia (visible small blood vessel dilation), Gum bleeding, Elevated hemoglobin | Injection site reactions, Headache, Nausea, Flushing |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: ACE-031 is investigational (in trials), while Gonadorelin is research-stage.
- Administration: ACE-031 — Subcutaneous injection; Gonadorelin — Subcutaneous injection, Intranasal (pulsatile delivery).
- Dosing units differ: ACE-031 is dosed in mg/kg, Gonadorelin in mcg — they operate at different scales.
- Frequency: ACE-031 is typically every 2–4 weeks (subcutaneous injection); Gonadorelin is 2–3x per week subcutaneous.
How each works
ACE-031
ACE-031 functions as a decoy receptor, binding myostatin, activin A/B, GDF-11, and BMP-9 in circulation before they can activate cellular ActRIIB receptors. In the Duchenne muscular dystrophy Phase 2 trial, ACE-031 produced meaningful lean body mass increases but was halted due to vascular side effects (epistaxis, telangiectasia) requiring dose and safety optimization.
Gonadorelin
Gonadorelin directly binds GnRH receptors in the anterior pituitary to trigger LH and FSH secretion, which in turn stimulates Leydig cells for testosterone production and maintains spermatogenesis. Used as a TRT adjunct, pulsatile gonadorelin administration mimics natural hypothalamic GnRH to prevent testicular suppression associated with exogenous androgen use.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.